Soleus Capital Management
Latest statistics and disclosures from Soleus Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KRYS, CELC, TGTX, PODD, NVCR, and represent 32.83% of Soleus Capital Management's stock portfolio.
- Added to shares of these 10 stocks: PODD (+$87M), UTHR (+$75M), VCEL (+$57M), KRYS (+$55M), INDV (+$39M), PGNY (+$35M), TGTX (+$30M), GERN (+$27M), ANIP (+$26M), MRK (+$24M).
- Started 25 new stock positions in CGEM, MRK, CORT, IMUX, ARWR, RLMD, TNDM, SOPH, SABS, TECX.
- Reduced shares in these 10 stocks: , , DXCM (-$73M), CELC (-$60M), BMRN (-$38M), GSK (-$31M), ELVN (-$31M), TWST (-$30M), RAPT (-$26M), .
- Sold out of its positions in ABVX, FOLD, ACLX, BCAX, BLTE, CAPR, CDTX, QDEL, DCTH, DYN.
- Soleus Capital Management was a net seller of stock by $-230M.
- Soleus Capital Management has $2.5B in assets under management (AUM), dropping by -8.92%.
- Central Index Key (CIK): 0001802630
Tip: Access up to 7 years of quarterly data
Positions held by Soleus Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Soleus Capital Management
Soleus Capital Management holds 93 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Krystal Biotech (KRYS) | 12.1 | $298M | +22% | 1.2M | 258.32 |
|
| Celcuity (CELC) | 5.9 | $147M | -28% | 1.3M | 114.14 |
|
| Tg Therapeutics (TGTX) | 5.4 | $134M | +28% | 4.0M | 33.22 |
|
| Insulet Corporation (PODD) | 4.8 | $118M | +275% | 563k | 209.84 |
|
| Novocure Ord Shs (NVCR) | 4.6 | $114M | +22% | 11M | 10.90 |
|
| United Therapeutics Corporation (UTHR) | 4.5 | $111M | +211% | 187k | 592.98 |
|
| Praxis Precision Medicines I Com New (PRAX) | 4.3 | $107M | -8% | 331k | 322.19 |
|
| Vericel (VCEL) | 3.3 | $82M | +233% | 2.5M | 32.17 |
|
| Alkermes SHS (ALKS) | 2.8 | $70M | +49% | 2.0M | 35.36 |
|
| Biosante Pharmaceuticals (ANIP) | 2.6 | $63M | +68% | 820k | 76.90 |
|
| Globus Med Cl A (GMED) | 2.5 | $63M | -17% | 730k | 86.16 |
|
| Geron Corporation (GERN) | 2.5 | $62M | +78% | 42M | 1.49 |
|
| Twist Bioscience Corp (TWST) | 2.4 | $58M | -34% | 1.2M | 47.52 |
|
| Edgewise Therapeutics (EWTX) | 1.8 | $46M | +59% | 1.4M | 31.50 |
|
| Beta Bionics (BBNX) | 1.8 | $44M | +71% | 4.4M | 10.02 |
|
| Alnylam Pharmaceuticals (ALNY) | 1.8 | $44M | +88% | 132k | 330.87 |
|
| Syndax Pharmaceuticals (SNDX) | 1.6 | $40M | -23% | 1.7M | 23.36 |
|
| Indivior Pharmaceuticals (INDV) | 1.6 | $39M | NEW | 1.3M | 30.48 |
|
| Neuropace (NPCE) | 1.6 | $39M | +8% | 2.9M | 13.15 |
|
| Livanova SHS (LIVN) | 1.5 | $37M | +2% | 583k | 63.56 |
|
| Mirum Pharmaceuticals (MIRM) | 1.5 | $37M | -30% | 400k | 92.38 |
|
| BioMarin Pharmaceutical (BMRN) | 1.5 | $37M | -50% | 651k | 56.49 |
|
| Progyny (PGNY) | 1.4 | $35M | NEW | 2.1M | 16.98 |
|
| Inspire Med Sys (INSP) | 1.2 | $30M | +92% | 576k | 51.58 |
|
| Edap Tms S A Sponsored Adr (EDAP) | 1.1 | $27M | 7.3M | 3.72 |
|
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 1.0 | $25M | -11% | 521k | 48.15 |
|
| Merck & Co (MRK) | 1.0 | $24M | NEW | 203k | 120.29 |
|
| Organogenesis Hldgs (ORGO) | 1.0 | $24M | 10M | 2.37 |
|
|
| Natera (NTRA) | 1.0 | $24M | +495% | 119k | 199.99 |
|
| Axogen (AXGN) | 0.9 | $23M | -43% | 679k | 33.13 |
|
| Vaxcyte (PCVX) | 0.9 | $22M | -36% | 386k | 58.11 |
|
| Icon SHS (ICLR) | 0.9 | $21M | NEW | 192k | 110.66 |
|
| Pharvaris N V (PHVS) | 0.8 | $20M | 702k | 28.25 |
|
|
| Cerus Corporation (CERS) | 0.8 | $20M | +168% | 11M | 1.82 |
|
| Trevi Therapeutics (TRVI) | 0.8 | $19M | +80% | 1.6M | 11.93 |
|
| Inhibikase Therapeutics Com New (IKT) | 0.7 | $18M | 11M | 1.68 |
|
|
| Context Therapeutics (CNTX) | 0.7 | $18M | NEW | 7.0M | 2.62 |
|
| Vir Biotechnology (VIR) | 0.7 | $18M | NEW | 2.0M | 8.96 |
|
| Xenon Pharmaceuticals (XENE) | 0.7 | $17M | NEW | 292k | 58.15 |
|
| Travere Therapeutics (TVTX) | 0.7 | $16M | NEW | 546k | 29.71 |
|
| Tandem Diabetes Care Com New (TNDM) | 0.6 | $15M | NEW | 783k | 19.17 |
|
| Nurix Therapeutics (NRIX) | 0.6 | $15M | -23% | 938k | 15.50 |
|
| Urogen Pharma (URGN) | 0.5 | $13M | +384% | 727k | 17.98 |
|
| Sionna Therapeutics (SION) | 0.5 | $12M | +9% | 294k | 40.09 |
|
| Corcept Therapeutics Incorporated (CORT) | 0.5 | $12M | NEW | 286k | 40.31 |
|
| Jade Biosciences Com New (JBIO) | 0.5 | $11M | 797k | 14.05 |
|
|
| Veracyte (VCYT) | 0.4 | $10M | +3099% | 320k | 32.21 |
|
| Adagio Therapeutics (IVVD) | 0.4 | $10M | 7.7M | 1.30 |
|
|
| C4 Therapeutics Com Stk (CCCC) | 0.4 | $10M | 3.8M | 2.63 |
|
|
| Orthopediatrics Corp. (KIDS) | 0.4 | $9.8M | +17% | 615k | 15.87 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.4 | $9.8M | -36% | 452k | 21.60 |
|
| Tango Therapeutics (TNGX) | 0.4 | $9.4M | +4400% | 450k | 20.92 |
|
| Evolus (EOLS) | 0.4 | $9.2M | +109% | 2.2M | 4.11 |
|
| Sophia Genetics Sa Ordinary Shares (SOPH) | 0.4 | $9.2M | NEW | 1.9M | 4.95 |
|
| Enliven Therapeutics (ELVN) | 0.4 | $9.1M | -77% | 231k | 39.20 |
|
| Inhibrx Biosciences (INBX) | 0.4 | $8.8M | +424% | 131k | 67.23 |
|
| Dex (DXCM) | 0.4 | $8.8M | -89% | 140k | 62.80 |
|
| Septerna (SEPN) | 0.3 | $6.6M | -28% | 275k | 24.03 |
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $6.6M | 442k | 14.93 |
|
|
| Biodesix (BDSX) | 0.2 | $6.0M | NEW | 417k | 14.50 |
|
| Relmada Therapeutics (RLMD) | 0.2 | $5.9M | NEW | 842k | 6.96 |
|
| Cullinan Oncology (CGEM) | 0.2 | $5.8M | NEW | 410k | 14.21 |
|
| Immunovant (IMVT) | 0.2 | $5.7M | -79% | 230k | 24.84 |
|
| Mbx Biosciences (MBX) | 0.2 | $5.3M | -56% | 179k | 29.85 |
|
| Immunic (IMUX) | 0.2 | $5.0M | NEW | 4.5M | 1.11 |
|
| Larimar Therapeutics (LRMR) | 0.2 | $4.8M | NEW | 1.1M | 4.50 |
|
| Eton Pharmaceuticals (ETON) | 0.2 | $4.1M | NEW | 166k | 24.68 |
|
| Sab Biotherapeutics Com New (SABS) | 0.2 | $4.0M | NEW | 1.1M | 3.83 |
|
| Procept Biorobotics Corp (PRCT) | 0.2 | $4.0M | NEW | 160k | 25.01 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.2 | $3.9M | -11% | 80k | 48.20 |
|
| Tectonic Therapeutic (TECX) | 0.2 | $3.8M | NEW | 122k | 30.91 |
|
| Pulmonx Corp (LUNG) | 0.1 | $3.6M | +36% | 2.8M | 1.29 |
|
| Iovance Biotherapeutics (IOVA) | 0.1 | $3.5M | NEW | 1.0M | 3.51 |
|
| Argenx Se Sponsored Adr (ARGX) | 0.1 | $2.6M | -88% | 3.5k | 730.25 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.1 | $2.5M | 440k | 5.57 |
|
|
| Satellos Bioscience | 0.1 | $2.3M | NEW | 414k | 5.63 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.1 | $1.8M | NEW | 29k | 62.70 |
|
| Inspiremd (NSPR) | 0.1 | $1.7M | -9% | 1.0M | 1.63 |
|
| Insmed Com Par $.01 (INSM) | 0.1 | $1.7M | -78% | 10k | 163.52 |
|
| Cytomx Therapeutics (CTMX) | 0.1 | $1.4M | NEW | 300k | 4.70 |
|
| Cg Oncology (CGON) | 0.1 | $1.4M | -88% | 20k | 67.68 |
|
| Neogenomics Com New (NEO) | 0.1 | $1.3M | -59% | 175k | 7.42 |
|
| Quoin Pharmaceuticals Sponsored Ads (QNRX) | 0.0 | $480k | +190% | 73k | 6.60 |
|
| Cogent Biosciences (COGT) | 0.0 | $385k | -91% | 10k | 38.49 |
|
| Tyra Biosciences (TYRA) | 0.0 | $383k | -92% | 10k | 38.30 |
|
| Staar Surgical Com Par $0.01 (STAA) | 0.0 | $374k | -20% | 20k | 18.70 |
|
| Anaptysbio Inc Common (ANAB) | 0.0 | $333k | -95% | 6.0k | 55.46 |
|
| Rapport Therapeutics (RAPP) | 0.0 | $313k | NEW | 10k | 31.29 |
|
| Rigel Pharmaceuticals (RIGL) | 0.0 | $270k | -96% | 10k | 27.04 |
|
| Zymeworks Del (ZYME) | 0.0 | $250k | -90% | 10k | 25.04 |
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.0 | $247k | 10k | 24.66 |
|
|
| Oruka Therapeutics (ORKA) | 0.0 | $245k | -97% | 5.0k | 49.05 |
|
| Jasper Therapeutics Com New (JSPR) | 0.0 | $242k | +38% | 276k | 0.88 |
|
Past Filings by Soleus Capital Management
SEC 13F filings are viewable for Soleus Capital Management going back to 2019
- Soleus Capital Management 2026 Q1 filed May 14, 2026
- Soleus Capital Management 2025 Q4 filed Feb. 12, 2026
- Soleus Capital Management 2025 Q3 filed Nov. 14, 2025
- Soleus Capital Management 2025 Q2 filed Aug. 15, 2025
- Soleus Capital Management 2025 Q1 filed May 15, 2025
- Soleus Capital Management 2024 Q4 filed Feb. 14, 2025
- Soleus Capital Management 2024 Q3 filed Nov. 14, 2024
- Soleus Capital Management 2024 Q2 filed Aug. 14, 2024
- Soleus Capital Management 2024 Q1 filed May 15, 2024
- Soleus Capital Management 2023 Q4 filed Feb. 14, 2024
- Soleus Capital Management 2023 Q3 filed Nov. 14, 2023
- Soleus Capital Management 2023 Q2 filed Aug. 14, 2023
- Soleus Capital Management 2023 Q1 filed May 15, 2023
- Soleus Capital Management 2022 Q4 filed Feb. 14, 2023
- Soleus Capital Management 2022 Q3 filed Nov. 14, 2022
- Soleus Capital Management 2022 Q2 filed Aug. 15, 2022